Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis

Ian N. Glaspole, Alice L. Watson, Heather Allan, Sally Chapman, Wendy A. Cooper, Tamera J. Corte, Samantha Ellis, Christopher Grainge, Nicole Goh, Peter Hopkins, Gregory Keir, Sacha Macansh, Annabelle Mahar, Yuben Moodley, Paul N. Reynolds, Christopher J. Ryerson, E. Haydn Walters, Christopher J. Zappala, Anne E. Holland
European Respiratory Journal 2017 50: 1700168; DOI: 10.1183/13993003.00168-2017
Ian N. Glaspole
1Dept of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia
2Monash University, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: i.glaspole@alfred.org.au
Alice L. Watson
3Discipline of Physiotherapy, Latrobe University, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heather Allan
4Lung Foundation Australia, Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sally Chapman
5Royal Adelaide Hospital, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wendy A. Cooper
6Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia
7Sydney Medical School, University of Sydney, Sydney, Australia
8School of Medicine, University of Western Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tamera J. Corte
9Dept of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia
10University of Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samantha Ellis
11Dept of Radiology, Alfred Hospital, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher Grainge
12Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, New Lambton Heights, Australia
13School of Medicine and Public Health, University of Newcastle, Callaghan, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicole Goh
1Dept of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia
14Institute of Breathing and Sleep, Austin Health, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Hopkins
15The Prince Charles Hospital, Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Keir
16Dept of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sacha Macansh
4Lung Foundation Australia, Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Annabelle Mahar
6Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia
7Sydney Medical School, University of Sydney, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuben Moodley
17Royal Perth Hospital, Perth, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul N. Reynolds
5Royal Adelaide Hospital, Adelaide, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Ryerson
18Dept of Medicine, University of British Columbia, Vancouver, BC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E. Haydn Walters
19University of Tasmania, Hobart, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Zappala
20Royal Brisbane and Women's Hospital, Brisbane, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne E. Holland
2Monash University, Melbourne, Australia
3Discipline of Physiotherapy, Latrobe University, Melbourne, Australia
21Dept of Physiotherapy, The Alfred Hospital, Melbourne, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anne E. Holland
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Prolonged anxiety and depression occur frequently in IPF and strongly relate to dyspnoea and cough http://ow.ly/iWxV30cLCfl

To the Editor:

We have recently shown that anxiety and depression are common comorbidities for people with interstitial lung disease (ILD). In a cross-sectional single-centre study, the prevalence of anxiety was 31% and the prevalence of depression was 23% [1]. Anxiety and depression were not related to physiological parameters; however, dyspnoea and number of comorbidities were important contributors. The aims of this study were to determine the frequency of prolonged anxiety and depression among sufferers of idiopathic pulmonary fibrosis (IPF), and factors contributing to their persistence.⇓

Using the Australian IPF Registry, we obtained data from all individuals who had completed the self-reported Hospital Anxiety and Depression Scale (HADS) at baseline and at 12 months of follow-up [2, 3]. HADS scores were classified according to standard criteria where a score >10 indicates a probable case of clinically significant anxiety or depression and a score of 8–10 indicates borderline probability. We defined prolonged anxiety and depression as being present when subjects had HADS scores ≥8 at baseline and at 12 months follow-up. We defined worsening risk of anxiety and depression as moving from “no case” to “borderline” or “case”, or moving from “borderline” to “case”, at 12 months.

Analysis included demographic and physiologic data, and patient-reported medical comorbidities. Breathlessness was measured using the UCSD shortness of breath questionnaire (UCSDSOBQ) which, like the HADS scale, explores symptoms over the preceding week [4]. Cough severity was rated using an unvalidated visual analogue scale (VAS), measured between 0 and 100 mm, with anchors of “no cough” and “worst cough imaginable” The persistence of anxiety and depression over 12 months of follow-up was evaluated using the Fisher's exact test. Univariate relationships were tested using Pearson's Chi-squared test for categorical variables and one-way analysis of variance for continuous variables. Variables with a relationship to prolonged anxiety or depression (p<0.1) were entered into a logistic regression model. Model fit and the proportion of participants correctly classified by the model were evaluated using the Chi-squared test.

At the time of analysis, the Australian IPF registry included 435 participants with probable or definite IPF (table 1). All 102 participants who had completed the HADS questionnaire at baseline and follow-up (12±3 months) were included. Comparison of this group with those excluded from analysis at baseline demonstrated no differences with respect to demographic or physiologic features. At the 12-month follow-up 96 participants had completed the HADS anxiety domain and 98 had completed the HADS depression domain.

View this table:
  • View inline
  • View popup
TABLE 1

Demographic data of participants at baseline and progress across 12 months

20 participants (21%) had prolonged anxiety, of whom 15 participants (75%) were not taking an anxiolytic. There was no association between prolonged anxiety and mortality (p=0.31). On univariate analysis, prolonged anxiety was associated with more severe baseline dyspnoea (p=0.008), supplemental oxygen use at baseline (p=0.035), suffering more comorbidities (p=0.005) and more severe baseline cough (p=0.07). There was no relationship with forced vital capacity (FVC) decline. On multivariate analysis, supplemental oxygen use was the only independent predictor of prolonged anxiety, and was associated with a 4.3 times greater odds of its presence (95% CI 1.142–15.636). There was a trend for association with cough severity (OR 1.023, 95% CI 0.997–1.049). The model correctly classified participants in 77% of cases.

13% of participants had a change in their HADS score to suggest worsening risk of anxiety over 12 months. On univariate analysis, worsening risk of anxiety was associated with change in cough severity over 12 months (mean increase 26 mm versus 2 mm, p=0.009), and worse dyspnoea at 12 months (UCSDSOBQ 94 versus 49 units, p=0.013). There was a trend for association with change in dyspnoea over 12 months (mean increase in UCSDSOBQ 37 versus 11 units points, p=0.06) and fall in FVC (mean −129 mL versus −30 mL, p=0.07). Multivariate analysis showed that only an increase in cough severity was an independent predictor of worsening risk of anxiety over 12 months (OR 1.056, 95% CI 1.011–1.104). A 10-mm increase on the cough severity scale was associated with a worsening risk of anxiety by 56%. This model correctly classified 93% of cases.

14 participants (14%) demonstrated prolonged depression, of whom 10 participants (71%) were not taking an antidepressant. On univariate analysis, prolonged depression was associated with worse baseline dyspnoea (p=0.004), worse baseline cough (p=0.03), more comorbidities (p=0.002), younger age (p=0.06) and worsening dyspnoea (p=0.07). There was no relationship with FVC decline. Multivariate analysis showed that prolonged depression was independently predicted by baseline cough severity (OR 1.045, 95% CI 1.012–1.080). A 10 mm increase in baseline cough severity increased the odds of prolonged depression by 45%.

7% of individuals had a worsening risk of depression over 12 months. Univariate analysis revealed associations with worse baseline dyspnoea (UCSDSOBQ mean 55 versus 36 units, p=0.046), worse dyspnoea at 12 months (80 versus 46 units, p=008) and change in dyspnoea (mean worsening 28 versus 10 units, p=0.006). 82% of individuals with a worsening risk of depression had two or more cormorbidities (p=0.017) and there were trends for association with greater worsening cough (41 versus 2 mm, p=0.08) and use of oxygen at 12 months (p=0.06). A change in FVC was not associated with worsening risk of depression. On multivariate analysis, only worsening dyspnoea was associated with a worsening risk of depression (OR 1.042, 95% CI 1.00–1.085). For each 1-unit increase in UCSDSOBQ over 12 months, the odds of a worsening risk of depression increased by 4%. This model correctly classified 89% of cases.

While previous cross-sectional research has demonstrated that depression is common among IPF sufferers, this study demonstrates that the tendency to anxiety and depression is retained over a 12-month period [5]. Pharmacologic therapy for anxiety and depression was being received in only approximately a quarter of cases, suggesting a large proportion are untreated. Further research is required to determine why this should be, with possibilities including that anxiety and depression are unrecognised, considered a normal response to IPF or thought refractory to treatment.

Our research confirms that dyspnoea is a major contributor to anxiety and depression and that another key IPF symptom, cough, is also an important contributor. The link between prolonged anxiety and depression and both cough and dyspnoea is demonstrated in a number of ways. On multivariate analysis, prolonged depression and cough were linked. While only oxygen usage was associated with anxiety on multivariate analysis, it has been previously demonstrated that ILD participants using oxygen perceive greater dyspnoea, and therefore in this study those variables are likely to demonstrate collinearity [6]. Finally, as cough and dyspnoea worsened, so too did the risk of anxiety and depression. The strong linkage seen between IPF symptoms and anxiety and depression raises the question of the direction of that relationship. Oxygen therapy was commonly added to our participants' therapy during the 12 months of longitudinal follow-up, but this did not appear to lessen the risk of anxiety. Whether the treatment of anxiety and depression might provide a route to the palliation of cough or dyspnoea remains an important question to explore.

This study has several limitations. We use the HADS scale at two time points to infer persistence of anxiety and depression rather than more thorough assessment as defined in current guidelines [7]. The validity of this instrument in detecting anxiety and depression is well established, but this has not been tested specifically in IPF [8, 9]. We used an unvalidated VAS measure of cough severity, potentially leading to imprecision. Additionally, we do not have a matched control population to determine the rates of prolonged anxiety and depression seen in the normal population.

Further research should examine the basis to prolonged anxiety and depression among sufferers of IPF. Any under recognition of anxiety and depression, or nihilism about their therapy should be addressed, given its strong linkage with IPF symptoms and health-related quality of life [10, 11]. Given the incomplete response of dyspnoea and cough to current palliative approaches, our findings suggest a further avenue for symptom control research via the treatment of anxiety and depression [12].

Disclosures

Supplementary Material

H. Allan ERJ-00168-2017_Allan

S. Chapman ERJ-00168-2017_Chapman

T.J. Corte ERJ-00168-2017_Corte

I.N. Glaspole ERJ-00168-2017_Glaspole

S. Macansh ERJ-00168-2017_Macansh

A. Mahar ERJ-00168-2017_Mahar

Y. Moodley ERJ-00168-2017_Moodley

P.N. Reynolds ERJ-00168-2017_Reynolds

E.H Walters ERJ-00168-2017_Walters

C.J. Zappala ERJ-00168-2017_Zappala

Acknowledgements

The researchers acknowledge the support to Australian IPF registry's national and state coordinators and its data manager in obtaining the data used for this research. I. Glaspole had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. I. Glaspole and A. Holland contributed substantially to the study design, data analysis and interpretation, and the writing of the manuscript. A. Watson contributed substantially to data analysis and interpretation and the writing of the manuscript. The remaining authors contributed substantially to the writing of the manuscript.

Footnotes

  • Support statement: This research was supported by the Lung Foundation of Australia via The Ivan Cash Research Award. The Australian IPF registry receives support from a philanthropic family, and unrestricted educational grants to the Lung Foundation of Australia from Roche, Boehringer-Ingelheim, Gilead Sciences and Bristol Myer Squibb. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received January 23, 2017.
  • Accepted May 13, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Holland AE,
    2. Fiore JF Jr.,
    3. Bell EC, et al.
    Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology 2014; 19: 1215–1221.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Moodley Y,
    2. Goh N,
    3. Glaspole I, et al.
    Australian Idiopathic Pulmonary Fibrosis Registry: vital lessons from a national prospective collaborative project. Respirology 2014; 19: 1088–1091.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Zigmond AS,
    2. Snaith RP
    . The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Eakin EG,
    2. Resnikoff PM,
    3. Prewitt LM, et al.
    Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest 1998; 113: 619–624.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Ryerson CJ,
    2. Arean PA,
    3. Berkeley J, et al.
    Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology 2012; 17: 525–532.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Olson AL,
    2. Brown KK,
    3. Swigris JJ
    . Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. Patient Relat Outcome Meas 2016; 7: 29–35.
    OpenUrl
  7. ↵
    Association AP. Diagnostic and statistical manual of mental disorders. 5th Edn. Arlington, American Psychiatric Association, 2013.
  8. ↵
    1. Bjelland I,
    2. Dahl AA,
    3. Haug TT, et al.
    The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res 2002; 52: 69–77.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Herrmann C
    . International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. J Psychosom Res 1997; 42: 17–41.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Ryerson CJ,
    2. Berkeley J,
    3. Carrieri-Kohlman VL, et al.
    Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest 2011; 139: 609–616.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Lechtzin N,
    2. Hilliard ME,
    3. Horton MR
    . Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. Chest 2013; 143: 1745–1749.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Vigeland CL,
    2. Horton MR
    . Cough in idiopathic pulmonary fibrosis: more than just a nuisance. Lancet Respir Med 2016; 4: 600–601.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 2 Table of Contents
European Respiratory Journal: 50 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis
Ian N. Glaspole, Alice L. Watson, Heather Allan, Sally Chapman, Wendy A. Cooper, Tamera J. Corte, Samantha Ellis, Christopher Grainge, Nicole Goh, Peter Hopkins, Gregory Keir, Sacha Macansh, Annabelle Mahar, Yuben Moodley, Paul N. Reynolds, Christopher J. Ryerson, E. Haydn Walters, Christopher J. Zappala, Anne E. Holland
European Respiratory Journal Aug 2017, 50 (2) 1700168; DOI: 10.1183/13993003.00168-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis
Ian N. Glaspole, Alice L. Watson, Heather Allan, Sally Chapman, Wendy A. Cooper, Tamera J. Corte, Samantha Ellis, Christopher Grainge, Nicole Goh, Peter Hopkins, Gregory Keir, Sacha Macansh, Annabelle Mahar, Yuben Moodley, Paul N. Reynolds, Christopher J. Ryerson, E. Haydn Walters, Christopher J. Zappala, Anne E. Holland
European Respiratory Journal Aug 2017, 50 (2) 1700168; DOI: 10.1183/13993003.00168-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Interstitial and orphan lung disease
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Airway immune responses to COVID-19 vaccination in COPD patients
  • Wider access to rifapentine-based regimens is needed for TB care globally
  • Screening for PVOD in heterozygous EIF2AK4 variant carriers
Show more Agora

Research letters

  • Translated impact on carbon footprint from choice of inhaled therapy
  • Radiographic score in TB and relationship to therapy and bacillary load
  • Single-inhaler triple versus dual bronchodilator therapy for GOLD “E” COPD patients
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society